Purpose: Evaluation of ketogenic diet (KD) therapies for seizure control during pregnancy when safety and appropriate management become considerations. Until now, no information has been available on seizure reduction and human pregnancy related outcomes in women treated with KD therapies. Method: We describe two cases of pregnant women with epilepsy treated with KD therapy either as monotherapy (Case 1) or as adjunctive therapy (Case 2). Results: Case 1: A 27 year old woman, gravida1, started the classic KD with medium chain triglyceride (MCT) emulsion and 75 g carbohydrate-restriction, later reduced to 47 g. Glucose levels were 4-6 mmol/L and blood ketone levels ranged from 0.2 to 1.4 mmol/L. Seizure frequency decreased and seizure-free days increased. Mild side effects included intolerance to MCT, reduced serum carnitine and vitamin levels, and mild hyperlipidemia. Fetal and neonatal growth was normal as was growth and development at 12 months. Case 2: A 36 year-old nulliparous woman was treated with a 20 gram carbohydrate-restricted Modified Atkins Diet (MAD) and lamotrigine, resulting in reduction of seizure frequency to once per month prior to pregnancy. Once pregnant, carbohydrates were increased to 30 g. When seizures increased, lamotrigine dose was doubled. Urine ketones trended down during second trimester. A male was born with bilateral ear deformities of unknown significance. The child had a normal neurodevelopment at eight months. Conclusion: Non-pharmacological epilepsy therapies like KD and MAD may be effective during human pregnancy. However, safety still has to be established. Further monitoring to identify potential long term side effects is warranted.
Introduction
Ketogenic diets (KD) are effective in the treatment of intractable epilepsy [1] [2] [3] [4] . Similar to classic KD, the Modified Atkins Diet (MAD) emphasizes high fat and low carbohydrate intake without restricting calories or protein intake. MAD is growing in popularity especially as treatment for adults with pharmacoresistent epilepsy, who are not offered a classic KD [2] . Increased use of KD in women of child-bearing age for seizure management raises questions about its safety as a gestational diet as there is a paucity of information on seizure control and pregnancy related parameters in mother and child [5] . In addition, concerns about anti-epileptic drug (AED) teratogenicity and altered pharmacokinetics during pregnancy emphasize the importance of identifying alternative "non-pharmacologic" measures of seizure control during pregnancy.
Patient 1
A 27-year-old woman was referred for KD therapy during her first pregnancy. She had a history of a right temporal brain tumor (pleiomorphic xanthoastrocytoma) which was partially resected at age 14 years. After a second partial resection following tumor progression at age 20 years, she experienced frequent focal seizures treated with valproic acid and oxcarbazepine. These drugs were discontinued because of side effects, with 3-5 brief focal seizures per day. She noticed excess carbohydrate intake led to increased frequency and duration of seizures, and self-initiated a carbohydrate-restricted diet (115 g/day) before becoming pregnant. At the first visit at 14 weeks of gestation, she had approximately two seizures per day and no seizure-free days. Classic KD was introduced by further reducing carbohydrate intake (75 g/day), increasing fat intake, and starting a Medium Chain Triglyceride (MCT) emulsion (50% MCT fat-50% water). After five weeks on KD, seizures declined to once daily and seizure-free days increased to two per week. The KD was adjusted frequently to improve seizure control (Table 1) .
Blood ketone levels ranged between 0.2-2.6 mmol/L during pregnancy. At 14 weeks gestation, a low total carnitine (TC) (18.3 mmol/L) normalized after supplementation with 20 mg/kg/ day. At 36 weeks gestation and after delivery, TC was elevated (60 mmol/L) despite reducing carnitine dose to 14 mg/kg/day and postpartum to 11.5 mg/kg/day. Folic acid, multivitamin and mineral supplementation were tailored as no multivitamin supplement in pregnancy was available matching the specific nutritional composition during KD. Nevertheless she had altered serum levels of vitamins A, D and E. Increased cholesterol and triglyceride values were noted during pregnancy. At 30 weeks of gestation she experienced gastrointestinal complaints after MCT consumption. MCT emulsion was replaced by ketogenic milk containing long chain fats, and was well tolerated.
The pregnancy proceeded uneventfully. Gestational weight gain was nine kilograms until delivery at 38.5 weeks gestation. A healthy male was born with normal Apgar scores, normal serum glucose levels and no urine ketones during the first 24 h after birth. Follow up showed normal neonatal growth; from 3.01 kg (z-score: À1.45) weight, 49 cm (z-score: À1.0) height, and 35 cm (z-score: À1) head circumference at birth, to 13.0 kg (z-score: +2) weight, 76 cm (z-score: À0.49) height and 48 cm (z-score: 0) head circumference at 12 months with normal neurodevelopment. The patient continued KD (47 g carbohydrates/day) after delivery and breastfed. Her weight decreased within one month to her antepartum weight. Four weeks after delivery, her fasting lipid profile normalized under unchanged diet composition.
Patient 2
A 36 year-old nulliparous woman with irritable bowel syndrome and borderline hyperlipidemia developed intractable complex partial seizures at age 14 years. She was initially treated with valproic acid, resulting in significant weight gain, and then subsequently carbamazepine with a baseline seizure frequency of 8 seizures per month. She started MAD (20 g net carbohydrates/ day) and moderate urine ketosis (2-4 mmol/L) was achieved after 1 week on the diet, and she was seizure-free when fat intake increased. In anticipation of planned pregnancy, she was transitioned to levetiracetam but began having breakthrough seizures, so started lamotrigine (LTG) therapy 1 year after initiating MAD. She was tapered off of levetiracetam and had 1 seizure per month on a combination of LTG 200 mg twice/day (level 6.9 mg/mL) and MAD (urine ketones 2-4 mmol/L). When she discovered she was 8 weeks pregnant, net carbohydrates were increased to 30 g per day. She continued supplements of 1 g of folic acid, calcium and 128 (20) 106 (17) 108 (17) 100 (15) 88 (15) 98 (17) 87 (17) 87 (17) 89 (18) Fat Total, (g, energy%)
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38 (14) 58 ( vitamin D, and began prenatal vitamin supplements. Urine ketones initially trended down to 0.5-1.5 mmol/L during the first trimester, then fluctuated between 0 and 4 mmol/L during the remainder of pregnancy despite increased carbohydrates. LTG blood levels ranged between 5.8 and 11.7 mg/mL. During pregnancy, seizures occurred 1-4 times per month and LTG was increased at 18 weeks (300 mg twice a day), 23 weeks (400/300 mg) and 32 weeks (400 mg twice a day) based on LTG serum levels. Gestational weight gain was 5.9 kg during pregnancy ( Table 2) . At 40 2/7 weeks gestation, she delivered by cesarean section due to cephalopelvic disproportion a healthy 2.88 kg (z-score: À1.13) and 51 cm (z-score: +0.38) male, with normal Apgar scores. The neonate had a left preauricular appendage and bilateral ear helical rim deformities with irregular borders but normal neonatal hearing tests. He had no other evident physical anomalies or malformations. The newborn metabolic screen laboratory studies showed a "borderline" free serum carnitine level. His development was normal at 6 months with a head circumference of 41.3 cm (z-score: À1.76) from 33.6 cm (z-score: À1.07) at birth. Following delivery, the patient's LTG dose was reduced to 300 mg twice a day. She chose not to breastfeed based on LTG use. The patient elected to taper off MAD, however she began to have breakthrough seizures at 60 g net carbohydrates per day, so returned to 35 g per day. At 8 months post-delivery, seizures continued and LTG was increased to 350 mg twice a day while still on MAD (Table 2 ).
Discussion
This is a description of women on KD therapies for epilepsy during pregnancy, either as monotherapy (Patient 1) or as adjunctive therapy (Patient 2).
For the first patient, seizures decreased in frequency within 5 weeks after initiating KD with moderate blood ketone levels. We did not aim to further increase ketone levels because the patient felt her mild seizures were tolerable. The question remains if potential benefits from further seizure reduction would outweigh the risks to fetal health caused by maternal hyperketonemia [5, 6] . Repeated measurements showed altered levels of total carnitine and fasting lipids. Although high fat intake may increase utilization of carnitine stores, deficiency during KD is not commonly present and supplementation rarely needed [7, 8] . In pregnancy, cholesterol and triglyceride requirements are increased due to enhanced fat tissue lipolytic activity [9] . KD can cause transient alterations in lipid levels that normalize with time [10] . We are not aware of any studies describing effects of altered carnitine or lipid levels during pregnancy on the fetus and/or pregnancy outcomes.
The second patient received a combination of MAD with LTG prior to becoming pregnant and experienced a slight increase in seizure frequency necessitating an adjustment in LTG dose. Decreased ketone levels might be a consequence of increasing the LTG dose [11] . It is also unclear whether the observed infant's mild ear deformities are coincidental or related to use of LTG, use of MAD, or advanced maternal age. Although ear malformations have been reported for infants exposed to other AEDs, such as valproic acid [12] , no reports have identified an association with LTGexposure. In mouse embryos of mothers on a KD, differences in embryo and organ volume were found in comparison to embryos of mothers on a standard mouse diet. While identified variations in mouse embryo development may indeed be due to embryo and organ energy substrate preference modulated by substrate concentration and availability in the maternal circulation [5] , it is unclear what the functional implications of these differences may be, and whether the KD has the same effect during adequate protein intake and normoglycemia. In the current report, the human newborns have not shown significant adverse effects related to gestational diet and had normal development in their first year of life. Our cases illustrate KD treatment during pregnancy as a nonpharmacological alternative to AEDs. In the absence of AED use, the neonate may safely be breastfed. Although the balance between risks and benefits should be evaluated on an individual basis, we would advocate for a standardized registration of women with epilepsy using ketogenic diets during pregnancy, including birth and long term outcomes (see Supplemental data for KD monitoring plan during pregnancy).
